Released Nov 6, 2024, after the close
10-Q filed Nov 7, 2024, 38 days after period end · 0001636422-24-000152
Q3 2024 · 10-Q
Revenue$76.35M$76.35M +3.5% vs Q3 2023+0.6% vs Q2 2024
Net Income-$14.73M-$14.73M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.24-$0.24 N/M vs Q3 2023N/M vs Q2 2024
Gross Profit$36,289,000—
Operating Income-$13,687,000N/M
Operating Cash Flowderived$6,208,000+99.3%
Free Cash Flowderived$5,503,000+85.5%
Margins · derived
Gross margin47.5%
Operating margin-17.9%+15.4 pt vs Q3 2023
Net margin-19.3%+10.6 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $76.35M | $73.77M | $68.35M | $61.74M |
| Net Income | -$14.73M | -$22.03M | -$45.74M | -$40.01M |
| EPS Diluted | -$0.24 | -$0.39 | -$0.84 | -$0.82 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Health Catalyst, Inc. · CIK 1636422 · Engraved from SEC EDGAR